Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma?

Neuro-Oncology

Volumn 13, Issue 10, 2011, Pages 1118-1124

  Clarke, Jennifer L ^a   Ennis, Michele M ^c   Yung, W K Alfred ^d   Chang, Susan M ^a   Wen, Patrick Y ^f   Cloughesy, Timothy F ^b   Deangelis, Lisa M ^g   Robins, H Ian ^h   Lieberman, Frank S ⁱ   Fine, Howard A ^j   Abrey, Lauren ^g   Gilbert, Mark R ^d   Mehta, Minesh ^k   Kuhn, John G ^e   Aldape, Kenneth D ^d   Lamborn, Kathleen R ^a   Prados, Michael D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c IQVIA   (United States)

^d UNIVERSITY OF TEXAS   (United States)

^e UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

^f DANA FARBER CANCER INSTITUTE   (United States)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^h University of Wisconsin Health   (United States)

ⁱ UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^j NATIONAL CANCER INSTITUTE   (United States)

^k NORTHWESTERN UNIVERSITY   (United States)

more..

Author keywords

Glioblastoma; PFS6; Prognosis; Recurrence; Surgery

Indexed keywords

AFLIBERCEPT; ANTINEOPLASTIC AGENT; CARBOPLATIN; CARMUSTINE; DESIPEPTIDE; EMD0121974; ERLOTINIB; FENRETINIDE; GEFITINIB; IMATINIB; IRINOTECAN; LAPATINIB; PAZOPANIB; RETINOIC ACID; SORAFENIB; TEMOZOLOMIDE; TEMSIROLIMUS; THALIDOMIDE; THYMIDINE; TIPIFARNIB; UNCLASSIFIED DRUG;

ADULT; AGED; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER REGISTRY; CANCER SURGERY; CONTROLLED STUDY; FEMALE; GLIOBLASTOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; REVIEW;

ADULT; AGED; BRAIN NEOPLASMS; CLINICAL TRIALS, PHASE II AS TOPIC; DISEASE-FREE SURVIVAL; FEMALE; GLIOBLASTOMA; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS;

EID: 80755159093     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nor110     Document Type: Review

References (5)

1. Lamborn KR, Yung WKA, Chang SM, et al. Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro-Onc. 2008;10:162-170.
2. Wu W, Lamborn KR, Buckner JC, et al. Joint NCCTG and NABTC prognostic factors analysis for high-grade recurrent glioma. Neuro-Onc. 2010;12:164-172.
3. Wong ET, Kenneth RH, Gleason MJ, et al. Outcome and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol. 1999;17:2572-2578. (Pubitemid 29368260)
4. Carson KA, Grossman SA, Fisher JD, et al. Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials. J Clin Oncol. 2007;25:2601-2606. (Pubitemid 47041234)
5. Macdonald DR, Cascino TL, Schold SC, Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8:1277-1280. (Pubitemid 20195640)